Summary of Rockwell Medical's Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Sales: $17.8 million for Q2 2026, an 11% increase from $16.1 million in Q2 2025. Year-to-date sales for the first half of 2026 were $35.1 million, consistent with the same period in 2025.

Gross Profit: Increased to $3.2 million (30% year-over-year improvement), with a gross margin of 18%, up from 16% in Q2 2025.

Net Loss: Reduced to $1.2 million in Q2 2026, compared to a loss of $1.5 million in Q2 2025.

Adjusted EBITDA: Negative $200,000 for Q2 2026, consistent with the prior year.

Cash Flow: Generated $2.1 million in cash from operations, ending the quarter with $24.8 million in cash and equivalents.

2Strategic Updates and Business Highlights

Rockwell Medical reported strong year-over-year growth driven by customer expansion and pricing actions.

Expanded customer base to approximately 300, including all five major U.S. dialysis providers and over 30 international markets.

Secured new agreements with Heritage Dialysis and renewed contracts with Aqua Dialysis, enhancing revenue predictability.

Continued operational improvements, including the activation of two automated production lines, aimed at increasing efficiency and reducing costs.

Focused on diversifying the product portfolio with new medical device opportunities that align with the existing renal care platform.

3Forward Guidance and Outlook

Reiterated full-year 2026 guidance: expected net sales between $70 million and $75 million, gross margin between 18% and 22%, and adjusted EBITDA between $1 million and $2 million.

Long-term goal to achieve annual net sales exceeding $100 million by 2029, with a target gross margin of approximately 30%.

4Bad News, Challenges, or Points of Concern

Despite improvements, the company continues to report net losses, indicating ongoing challenges in reaching profitability.

The reliance on a few key customers remains a concern, although efforts to diversify the customer base are ongoing.

Market conditions and competitive pressures in the dialysis supply sector could pose risks to growth and margin expansion.

5Notable Q&A Insights

Management emphasized the strategic importance of expanding operations in the West Coast, where they see significant market opportunities.

Contracts with partners typically last around three years, with discussions for renewals starting six months prior to expiration.

The new medical device opportunity is expected to complement existing products and is being funded within the current operating plan without the need for additional capital raises.

Incremental growth in the West Coast is expected to carry margins higher than the corporate average, indicating potential for improved profitability in that region. Overall, Rockwell Medical demonstrated solid financial performance in Q2 2026, with strategic initiatives aimed at long-term growth and operational efficiency, despite ongoing challenges related to profitability and market competition.